Katherine McElwain, PA
Medical · Rochester, NYNPI 1386998300
Payments from drug & device makers
Across 81 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$290
- Sumitomo Pharma America, Inc.$216
- AbbVie$189
- Exeltis, USA Inc.$179
- Novo Nordisk$129
- Astellas Pharma US Inc$123
- plus $710 from 14 others
What the payments were for
- Food & beverage$1,836100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 12 | $290 |
| Sumitomo Pharma America, Inc. | 9 | $216 |
| AbbVie | 9 | $189 |
| Exeltis, USA Inc. | 7 | $179 |
| Novo Nordisk | 7 | $129 |
| Astellas Pharma US Inc | 4 | $123 |
| Biogen | 4 | $115 |
| Exact Sciences | 4 | $111 |
| Lilly USA, LLC | 3 | $79 |
| Millicent US Inc | 4 | $66 |
| Hologic Sales And Service, LLC | 3 | $66 |
| Pfizer | 4 | $65 |
| Merck | 2 | $37 |
| Agile Therapeutics, Inc. | 2 | $36 |
| Bayer | 2 | $32 |
| Organon | 1 | $28 |
| Dexcom, Inc. | 1 | $24 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $19 |
| Scynexis, Inc. | 1 | $12 |
How this compares
$1,836 in reported general payments places this provider in the 75th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 37 | $2,788 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 54 | $1,009 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 16 | $771 |
| ValacyclovirValacyclovir Hcl | 25 | $734 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 40 | $612 |
| Nystatin | 29 | $410 |
| Fluconazole | 68 | $304 |
| Alendronate Sodium | 24 | $278 |
| Metronidazole | 14 | $213 |
Paid to pharmacies, not to this prescriber.
Other medical in Rochester
- Gina FriesRochester$106K
- Brandon YehlRochester$24K
- Michael BrownRochester$16K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Ilse StraussSmithtown$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.